Continuous bioprocessing set to revolutionize cGMP manufacturing of biologics
Read the article describing the latest trends in the biopharmaceutical industry
Read the article describing the latest trends in the biopharmaceutical industry
Read the article on our continuous bioprocess platform used at J.POD
Read the article about how to rapidly develop and manufacture mAb-based therapeutics
Read the article on why early mAb optimization might be right for your project.
Read the article on our continuous manufacturing technologies used in our cGMP manufacturing facility J.POD.
Read the article on our cGMP manufacturing facility J.POD in the June edition of BioProcess Int.
In recent years, the multi-attribute method (MAM) has become an important mass spectrometry-based tool for identifying and quantifying the site-specific product attributes and purity information…
Current methods for stably expressing biotherapeutics in CHO cells often rely on random or semi-random integration events which result in widely heterogeneous cell populations. In…
The 11th edition is dedicated to our exciting new capabilities in the biologics lane of Evotec’s “Multi-modality Autobahn.” For the biologics industry, Evotec provides a…
What are antibodies? Antibodies, or immunoglobulin molecules, are glycoproteins produced by the plasma B cells of the adaptive immune system with the aim to recognise…
Antibody discovery may be driven by the interrogation of two primary sources: (1) in vivo (animal-derived B cells) or (2) in vitro (library-derived antibody display…
What is FFmab screening? FFmab screening is a platform for identifying novel functional antibodies that change disease-modifying phenotypes of immune cells. The platform identifies innovative…